연구동향 분석

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by hemotherapy

이희연 김훈교 이경희 김봉석 송홍석 양성현 김준희 김열홍 김종광 김상위 김시영 박희숙 김동완 2014년

논문상세정보
인용/피인용
' A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by hemotherapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • antineoplastic agents
  • azasetron
  • ondansetron
  • serotoninantagonists
  • vomiting
  • vomiting/chemicallyinduced
  • vomiting/preventionandcontrol
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,325 0

0.0%

' A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by hemotherapy' 의 참고문헌

  • Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
    Latreille J J Clin Oncol 16 : 1174 ~ 1178 [1998]
  • Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
    Latreille J J Clin Oncol 16 1174-1178 [1998]
  • The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Pater JL Ann Oncol 8 : 181 ~ 185 [1997]
  • The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Pater JL Ann Oncol 8 181-185 [1997]
  • The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis
    Haga K Jpn J Pharmacol 63 : 377 ~ 383 [1993]
  • The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis
    Haga K Jpn J Pharmacol 63 377-383 [1993]
  • Synthesis of 5-HT3 receptor antagonists, [11C] Y-25130 and [11C] YM060
    Ishiwata K Appl Radiat Isot 46 : 907 ~ 910 [1995]
  • Synthesis of 5-HT3 receptor antagonists, [11C] Y-25130 and [11C] YM060
    Ishiwata K Appl Radiat Isot 46 907-910 [1995]
  • Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP
    Kimura E Gan To Kagaku Ryoho 23 : 477 ~ 481 [1996]
  • Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP
    Kimura E Gan To Kagaku Ryoho 23 477-481 [1996]
  • Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications
    Geling O J Clin Oncol 23 : 1289 ~ 1294 [2005]
  • Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications
    Geling O J Clin Oncol 23 1289-1294 [2005]
  • Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis
    Perez EA J Clin Oncol 13 : 1036 ~ 1043 [1995]
  • Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis
    Perez EA J Clin Oncol 13 1036-1043 [1995]
  • Rankings and symptom assessments of side effects from chemotherapy : insights from experienced patients with ovarian cancer
    Sun CC Support Care Cancer 13 : 219 ~ 227 [2005]
  • Rankings and symptom assessments of side effects from chemotherapy : insights from experienced patients with ovarian cancer
    Sun CC Support Care Cancer 13 219-227 [2005]
  • Proposal for classifying the acute emetogenicity of cancer chemotherapy
    Hesketh PJ J Clin Oncol 15 : 103 ~ 109 [1997]
  • Proposal for classifying the acute emetogenicity of cancer chemotherapy
    Hesketh PJ J Clin Oncol 15 103-109 [1997]
  • Potential of substance P antagonists as antiemetics
    Diemunsch P Drugs 60 : 533 ~ 546 [2000]
  • Potential of substance P antagonists as antiemetics
    Diemunsch P Drugs 60 533-546 [2000]
  • Pharmacokinetics of azasetron(Serotone), a selective 5-HT3 receptor antagonist
    Tsukagoshi S Gan To Kagaku Ryoho 26 : 1001 ~ 1008 [1999]
  • Pharmacokinetics of azasetron(Serotone), a selective 5-HT3 receptor antagonist
    Tsukagoshi S Gan To Kagaku Ryoho 26 1001-1008 [1999]
  • Pathogenesis-based treatment of chemotherapyinduced nausea and vomiting : two new agents
    Navari RM J Support Oncol 1 : 89 ~ 103 [2003]
  • Pathogenesis-based treatment of chemotherapyinduced nausea and vomiting : two new agents
    Navari RM J Support Oncol 1 89-103 [2003]
  • High affinity binding of Y-25130 for serotonin 3 receptor
    Sakamori M Nihon Yakurigaku Zasshi 100 : 137 ~ 142 [1992]
  • High affinity binding of Y-25130 for serotonin 3 receptor
    Sakamori M Nihon Yakurigaku Zasshi 100 137-142 [1992]
  • Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret
    Rudd JA Neuropharmacology 33 : 1607 ~ 1608 [1994]
  • Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret
    Rudd JA Neuropharmacology 33 1607-1608 [1994]
  • Dose-independent pharmacokinetics of ondansetron in rats : contribution of hepatic and intestinal first-pass effects to low bioavailability
    Yang SH Biopharm Drug Dispos 29 : 414 ~ 426 [2008]
  • Dose-independent pharmacokinetics of ondansetron in rats : contribution of hepatic and intestinal first-pass effects to low bioavailability
    Yang SH Biopharm Drug Dispos 29 414-426 [2008]
  • Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
    N Engl J Med 342 : 1554 ~ 1559 [2000]
  • Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
    N Engl J Med 342 1554-1559 [2000]
  • Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers
    Simpson KH Psychopharmacology(Berl) 109 : 497 ~ 498 [1992]
  • Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers
    Simpson KH Psychopharmacology(Berl) 109 497-498 [1992]
  • Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy : a randomized controlled trial
    Cheirsilpa A Jpn J Clin Oncol 35 : 695 ~ 699 [2005]
  • Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy : a randomized controlled trial
    Cheirsilpa A Jpn J Clin Oncol 35 695-699 [2005]
  • Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients
    Hayakawa T Gan To Kagaku Ryoho 33 : 633 ~ 638 [2006]
  • Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients
    Hayakawa T Gan To Kagaku Ryoho 33 633-638 [2006]
  • Comparison of Azasetron and Ondansetron for Preventing Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery
    윤미자 Yonsei Medical Journal 51 (1) : 88 ~ 92 [2010]
  • Comparison of Azasetron and Ondansetron for Preventing Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Laparoscopic Surgery
    윤미자 Yonsei Medical Journal 51 1 88-92 [2010]
  • Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
    Navari R J Clin Oncol 13 : 1242 ~ 1248 [1995]
  • Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
    Navari R J Clin Oncol 13 1242-1248 [1995]
  • Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP
    Kimura E Gan To Kagaku Ryoho 24 : 855 ~ 859 [1997]
  • Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP
    Kimura E Gan To Kagaku Ryoho 24 855-859 [1997]
  • Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets
    Huskey SE Drug Metab Dispos 31 : 785 ~ 791 [2003]
  • Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets
    Huskey SE Drug Metab Dispos 31 785-791 [2003]
  • Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin
    Yamada Y Yakugaku Zasshi 127 : 353 ~ 357 [2007]
  • Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin
    Yamada Y Yakugaku Zasshi 127 353-357 [2007]
  • A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin
    Tsukuda M Gan To Kagaku Ryoho 22 : 1959 ~ 1967 [1995]
  • A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin
    Tsukuda M Gan To Kagaku Ryoho 22 1959-1967 [1995]